This canonical paper page includes Commercialization Proof and Related Resources.
ARXIV:2603.15047 · MEDICAL AI · SUBMITTED 19 MAR · 18:48 UTC · FRESHNESS STALE
ARXIV:2603.15047MEDICAL AISUBMITTED 19 MAR · 18:48 UTCFRESHNESS STALEarXiv
CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks.
Opportunity summary
Pain CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks.
Evidence 0 refs | 0 sources | 33% coverage
Blocker Evidence unverified
CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks. The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and precision medicine.
Combination pharmacotherapy offers substantial therapeutic advantages but also poses substantial risks of adverse drug reactions (ADRs). The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and…
ScienceToStartup currently rates this 8.0/10 on the public viability pass. Systematic evaluation on the newly constructed CrossADR-Dataset-covering 1,376 drugs and 946,000 unique combinations-demonstrates that CrossADR consistently achieves state-of-the-art performance across 80 distinct experimental scenarios…
Medical AI moved forward this cycle; last verified April 2026. Public score 8.0/10.
Continue into Read for claims, analysis, references, and neighboring papers.
mobile layout uses overflow-hidden min-w-0 break-wordsOpportunity summary
Score8.0Public score shown from the verified overall while the stale axis breakdown refreshesAnalysis summary
CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks.
Loading BUILD…
Paper Pack
10.48550/arXiv.2603.15047CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks.
Abstract
Combination pharmacotherapy offers substantial therapeutic advantages but also poses substantial risks of adverse drug reactions (ADRs). The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and precision medicine. However, managing ADRs remains a challenge due to the vast search space of drug combinations and the complexity of physiological responses. Current graph-based architectures often struggle to effectively integrate multi-scale biological information and frequently rely on fixed association matrices, which limits their ability to capture dynamic organ-level dependencies and generalize across diverse datasets. Here we propose CrossADR, a hierarchical framework for organ-level ADR prediction through cross-layer feature integration and cross-level associative learning. It incorporates a gated-residual-flow graph neural network to fuse multi-scale molecular features and utilizes a learnable ADR embedding space to dynamically capture latent biological correlations across 15 organ systems. Systematic evaluation on the newly constructed CrossADR-Dataset-covering 1,376 drugs and 946,000 unique combinations-demonstrates that CrossADR consistently achieves state-of-the-art performance across 80 distinct experimental scenarios and provides high-resolution insights into drug-related protein protein interactions and pathways. Overall, CrossADR represents a robust tool for cross-scale biomedical information integration, cross-layer feature integration as well as cross-level associative learning, and can be effectively utilized to prevent ADRs in clinical decision-making.
Source availability
PDF linkedThe paper record includes a public PDF URL.
Extraction status
Derived fallbackRead summaries are estimated from adjacent metadata, not verified extraction rows.
Proof status
unverified0 refs; 0 sources; 33% coverage.
What was readable
Derived fallback: Estimated from adjacent evidence; not verified from source.
Viability
Time to MVP
Commercial
Export
Preparing verified analysis
Dimensions overall score 8.0
PROBLEM
CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks. The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and precision medicine.
METHOD
Combination pharmacotherapy offers substantial therapeutic advantages but also poses substantial risks of adverse drug reactions (ADRs). The accurate prediction of ADRs with interpretable computational methods is crucial for clinical safety management, drug development, and prec...
RESULT
ScienceToStartup currently rates this 8.0/10 on the public viability pass. Systematic evaluation on the newly constructed CrossADR-Dataset-covering 1,376 drugs and 946,000 unique combinations-demonstrates that CrossADR consistently achieves state-of-the-art performance across 80...
WHY NOW
Medical AI moved forward this cycle; last verified April 2026. Public score 8.0/10.
demonstrates that CrossADR consistently achieves state-of-the-art performance across 80 distinct experimental scenarios
The abstract explicitly states 'demonstrates that CrossADR consistently achieves state-of-the-art performance'.
partial
It incorporates a gated-residual-flow graph neural network to fuse multi-scale molecular features
The abstract clearly describes the technical approach used in CrossADR.
partial
utilizes a learnable ADR embedding space to dynamically capture latent biological correlations across 15 organ systems
The abstract details the specific mechanism for capturing biological correlations.
partial
Systematic evaluation on the newly constructed CrossADR-Dataset-covering 1,376 drugs and 946,000 unique combinations-
The abstract provides specific details about the dataset used for evaluation.
partial
and provides high-resolution insights into drug-related protein protein interactions and pathways.
The abstract states this as a benefit and outcome of the evaluation.
partial
Current graph-based architectures often struggle to effectively integrate multi-scale biological information
This is presented as a limitation of existing methods, motivating the development of CrossADR.
partial
and can be effectively utilized to prevent ADRs in clinical decision-making.
The abstract concludes with the practical application of the framework.
partial
Paper-native neighborhood for concepts, methods, materials, markets, and competitors. Missing lanes stay labeled instead of disappearing behind commercialization gates.
Concepts
Methods
Materials
Markets
Competitors
CrossADR enhances adverse drug reactions prediction for combination pharmacotherapy using advanced graph neural networks.
Segment
Medical AI
Adoption evidence
No public code link in the paper record yet
Commercial read
8.0/10 public viability
Direct
Adjacent
Substitute
Unknown
No indexed public discussion is attached to 2603.15047 yet. That is a visibility signal, not a blank module: the monitor is watching the public channels below.
Hacker News
Not indexed yet
Not indexed yet
Bluesky
Not indexed yet
Preview the source document here, or use the hero PDF action for a new tab.
Reference metadata is not materialized in the public index yet. The source PDF remains the authority; cache refresh is optional.
CITED BY
No citing papers are indexed in the public S2S graph yet. This is an explicit zero-signal state, not a hidden lookup.
Foundation
Extension
Commercially relevant
Conflicting
Owned Distribution
Get the weekly shortlist of commercializable papers, benchmark movers, and proof receipts that matter for product execution.
0/3 checks · 0%
Build Passport
Build passport pending - Proof Lab budget No verified cost estimate / $7.00 cap
status
missing
reason
passport_row_missing
proof status
unverified
cost/budget
No verified cost estimate
confidence low
next verification path
Build brief missing until Build Passport data exists.
Source missing: Build Passport payload.
Experiment plan missing until prototype path is available.
No prototype path attached.
Validation checklist missing until required assets, cost, and regulatory flags are verified.
No checklist artifact is attached to the Build Passport payload.
Derived signals show verified:false until source-backed receipts exist.
Evidence coverage
OpportunityKernel evidence_receipt
0 refs / 0 sources / 33% coverage
stale
Verify missing sources before using this as buyer proof. verified:false
Build readiness
BuildPassport EvidenceState
passport absent
stale
Run Proof Lab or inspect typed missing state. verified:false
Artifact maturity
GitHub and Hugging Face maturity payloads
No public artifact surface observed
stale
Open source artifacts or mark the gap as missing. verified:false
Technical feasibility
partial
Current read
Runnable path is not fully verified.
Evidence
No Build Passport payload attached.
Gaps
Next test
Run minimal reproduction from the Build Passport prototype path.
Market urgency
missing
Current read
Buyer urgency is not verified from source.
Evidence
0 references, 0 sources, 33% evidence coverage.
Gaps
Next test
Collect buyer interview, deployment evidence, or cited demand signal.
Buyer clarity
missing
Current read
No budget owner is verified for this paper.
Evidence
Build tab has no CRM, procurement, or operator source.
Gaps
Next test
Map target operator, economic buyer, and procurement trigger.
Defensibility
missing
Current read
Defensibility signals are missing.
Evidence
No defensibility receipt attached.
Gaps
Next test
Refresh defensibility bars with source receipts.
Integration burden
missing
Current read
No public implementation surface observed.
Evidence
No GitHub or Hugging Face payload attached.
Gaps
Next test
Write integration checklist from prototype path and target workflow.
Capital intensity
missing
Current read
No observed cost estimate is verified.
Evidence
Cost passport has no observed_usd value.
Gaps
Next test
Run cost passport or mark the cost field not applicable.
Regulatory load
missing
Current read
No regulatory classification is attached.
Evidence
Build Passport ledger does not include regulatory flags.
Gaps
Next test
Classify regulatory flags before commercialization planning.
No named scientific founder assigned.
Paper authors are not treated as operators without consent.
People
No named person assigned.
Gaps
Next verification path
Prototype owner missing.
Build Passport does not name an implementer.
People
No named person assigned.
Gaps
Next verification path
Operator workflow not sourced.
No buyer or workflow interview attached.
People
No named person assigned.
Gaps
Next verification path
No GTM owner verified.
No CRM or outreach source attached.
People
No named person assigned.
Gaps
Next verification path
Regulatory need unclassified.
No clinical or regulatory source attached.
People
No named person assigned.
Gaps
Next verification path
ARTIFACTS
No public artifacts yet.
DEFENSIBILITY
Defensibility and confidence evidence pending.
WATCHTOWER
No verified watchtower monitor rows yet.
FORESIGHT
No prediction yet — minted on next Foresight batch.
OPPORTUNITYKERNEL CHANGES SINCE LAST VIEW
No verified OpportunityKernel changes since the last view.
COMPETITIVE LANDSCAPE UPDATES
No verified competitive landscape changes yet.
RELATED PAPER UPDATES
No verified related paper changes yet.
SIGNAL CANVAS HISTORY AND DELTAS
No Signal Canvas history deltas yet.
TIMELINE
Save this paper to start tracking momentum - commits, demos, and score changes appear here.
No tracked events yet.
Score trend will appear after multiple data points.
BUZZ
Buzz trend pending.